What does Integer Holdings do?
Integer Holdings Corporation is a medical-device contract development and manufacturing organization, or CDMO. It helps large original equipment manufacturers design, engineer, validate, manufacture, coat, assemble, and support regulated medical products. Its core exposure is not to hospitals or patients directly, but to the supply chains of medical-device companies serving cardio and vascular, cardiac rhythm management, and neuromodulation markets. The company describes itself as one of the world’s largest medical-device CDMOs on its investor-relations overview.
Which products and customers define the business?
The portfolio ranges from guidewires, catheters, delivery systems, coatings, micro-machined components, and vascular implants to batteries, capacitors, feedthroughs, implantable pulse-generator components, leads, and finished assemblies. Integer can participate from early engineering through commercial-scale production, which matters because medical devices require documented quality systems, validated manufacturing processes, regulatory support, and long product lives.
Why does Integer matter in medtech?
Integer matters because outsourcing allows device OEMs to access specialized process technology, global capacity, and quality systems without recreating every capability internally. The company operates as one reportable segment, but its three product lines reveal where economic value is concentrated. Its scale, regulated manufacturing footprint, and ability to combine components with assemblies make it more than a commodity job shop. The detailed scope is set out in the company’s 2025 Form 10-K.
How does Integer make money, and which product lines matter most?
Integer earns revenue by selling engineered components, subassemblies, finished devices, coatings, and development services to medical-device OEMs. Pricing reflects material content, engineering complexity, quality requirements, production volume, capital invested, and the customer’s position in the product life cycle. Revenue can be recognized at shipment or over time when contractual terms make the customer control work in process; in Q1 2026, over-time recognition represented 38% of total revenue.
What drives revenue and margin by product line?
| Product line | Revenue logic | Main margin drivers | Current interpretation |
|---|---|---|---|
| Cardio & Vascular | Components, delivery systems, coatings, catheters, guidewires, implants, and development work | New-product ramps, mix, utilization, coating and machining differentiation | Primary growth engine; FY2025 sales rose 17% |
| CRM & Neuromodulation | Implantable power, feedthroughs, leads, electrodes, cases, and assemblies | Program volumes, customer demand, technology content, long qualification cycles | Large, durable base with uneven customer-program timing |
| Other Markets | Non-core surgical and portable-medical products | Exit timing, transfer costs, and fixed-cost absorption | Shrinking by design rather than representing a growth franchise |
How concentrated is the customer base?
Customer concentration is central to the model. Abbott, Boston Scientific, and Medtronic collectively represented 49% of FY2025 sales. In Q1 2026, the three largest disclosed customers represented 19%, 18%, and 15% of revenue. Those relationships can create recurring volume and deep operational integration, but they also increase buyer power and expose Integer to forecast changes, dual sourcing, insourcing, and OEM program decisions.
Why do product development and manufacturing scale create a moat?
Integer’s competitive advantage is a bundle of capabilities rather than a single patent or consumer brand. Medical-device manufacturing requires validated equipment, documented process controls, traceability, supplier qualification, regulatory discipline, and consistent quality. Once a supplier is designed into an approved product and performs reliably, changing that supplier can require engineering work, revalidation, regulatory documentation, and operational risk. Those frictions create switching costs, especially for implantable and high-risk devices.
Which resources are genuinely difficult to replicate?
The most defensible resources are process know-how in miniaturization, batteries, capacitors, feedthroughs, coatings, micro-machining, catheters, and delivery systems; ISO 13485-certified quality systems; a footprint spanning the United States, Ireland, Mexico, the Dominican Republic, Uruguay, Malaysia, and other locations; and the credibility to supply leading OEMs. Integer also benefits from breadth: it can offer a coating, a component, an assembly, or a broader development-to-commercialization package.
What limits the moat?
The same OEMs that value Integer’s capabilities are sophisticated buyers with scale. They can negotiate pricing, diversify suppliers, or bring production in-house. Fixed manufacturing costs also mean that lost volume can compress margins quickly. The moat therefore depends on execution: service, quality, delivery, responsiveness, and continued technical differentiation. Integer’s mission—advancing customer goals through engineering and manufacturing—matters because it directs the company toward partnership and speed to market rather than merely selling factory capacity.
Which strategic turning points shaped Integer’s current portfolio?
-
1970Wilson Greatbatch founded the predecessor around implantable-device battery technology, establishing the company’s enduring position in active implants.
-
2015The Lake Region Medical acquisition broadened vascular, catheter, and outsourced manufacturing capabilities, transforming scale and customer reach.
-
2016The Nuvectra spin-off separated proprietary neuromodulation-device assets, while the corporate rename to Integer and ticker change to ITGR reflected a broader CDMO model.
-
2018The Advanced Surgical and Orthopedic divestiture reduced portfolio breadth and sharpened focus on higher-growth medtech markets.
-
2021–2026The planned Portable Medical exit reallocates capacity away from a lower-priority activity, although the wind-down temporarily reduces Other Markets revenue.
-
2022–2025Aran Biomedical, Pulse Technologies, Precision Coating, VSi Parylene, and Biocoat added textiles, machining, and specialized coatings to the Cardio & Vascular toolkit.
-
2025–2026Payman Khales became CEO, activist engagement reshaped the board, and the company initiated a strategic review of standalone and transaction alternatives.
Why does this history still matter?
The historical pattern is consistent: expand differentiated medtech capabilities, exit less strategic businesses, and use acquisitions to become a broader partner to large OEMs. The 2015 combination explains today’s scale; the 2016 rename captured the shift from a battery-centered identity to an integrated platform; and the Aran acquisition and later tuck-ins moved the company closer to end-to-end vascular solutions.
What does Integer’s latest quarter show?
The quarter ended April 3, 2026 showed a sharp change in mix and profitability. Sales were nearly flat, but gross profit declined as lower production volumes reduced fixed-cost absorption. GAAP net income was $16.5 million, while adjusted operating income was $61.1 million and adjusted EBITDA was $85.1 million. Management linked the near-term pressure to three new-product headwinds and reduced its 2026 outlook while maintaining an objective of returning to 200 basis points above-market organic growth in 2027. The complete reconciliation is in the Q1 2026 earnings release.
Which product-line signals were strongest or weakest?
| Q1 2026 metric | Reported result | Year-over-year signal | Interpretation |
|---|---|---|---|
| Cardio & Vascular sales | $261.7M | Up 1.1% | Acquisition contribution and currency partly offset electrophysiology product headwinds |
| CRM & Neuromodulation sales | $168.3M | Up 4.9% | Cardiac rhythm growth outweighed lower demand from a neuromodulation customer |
| Other Markets sales | $9.6M | Down 47.3% | Mostly reflects the planned Portable Medical exit |
| Operating cash flow | $24.7M | Below prior year | Inventory growth and accrued-liability outflows limited cash conversion |
How does the quarter compare with the annual growth trend?
How strong are margins, cash flow, and the balance sheet?
Integer is profitable and generates operating cash, but it is capital intensive and acquisition funded. FY2025 gross profit was $500.4 million, operating income was $221.3 million, and net income was $102.8 million. Operating cash flow was $196.1 million, while capital expenditure was $91.0 million, implying simple free cash flow of about $105.1 million before acquisition spending and financing activity.
Margin fell from the prior-year quarter as lower volume reduced fixed-cost absorption. For a manufacturing CDMO, utilization and mix can matter as much as revenue growth.
What does cash conversion reveal?
The first-quarter bridge is not a full-year run rate, but it shows why working capital matters. Inventory increased substantially during Q1 2026 while accounts receivable improved. In a DCF, normalized free cash flow should therefore be based on a multi-period view of operating cash flow, capital expenditure, and working-capital investment rather than one quarter alone.
How much financial flexibility remains?
| Balance-sheet item | Period | Amount | Research implication |
|---|---|---|---|
| Total debt | April 3, 2026 | $1.252B | Debt rose after the company funded repurchases and investments |
| Cash and equivalents | April 3, 2026 | $8.1M | Liquidity relies more on cash generation and committed borrowing capacity than idle cash |
| Net leverage | April 3, 2026 | 3.2× adjusted EBITDA | Manageable under covenants, but meaningful for a cyclical manufacturing model |
| Share repurchase | Q1 2026 | $50.0M | Capital allocation favored stock retirement despite near-term operating pressure |
The underlying filing detail, including debt, working capital, and cash-flow movements, is available in the Q1 2026 Form 10-Q.
Who competes with Integer, and where is its market position?
Integer does not publish a definitive named peer list in its 10-K because competition varies by product, capability, and geography. The practical competitive set includes specialist medical-device CDMOs, niche coating and component suppliers, diversified manufacturing groups, and customers’ own internal factories. Rivalry occurs at every phase: new-product development, redesign, transfer of mature product lines, and commercial production.
What determines competitive success?
The filing identifies reputation, quality, delivery, responsiveness, design and engineering breadth, price, customer relationships, and complete supply-chain solutions as the main competitive factors. Integer’s global footprint and technology portfolio create barriers to entry, but market share is not disclosed and should not be inferred. The strongest evidence of market position is behavioral: a substantial backlog, repeat business with global OEMs, and customer willingness to fund some development programs.
| Competitive force | Pressure on Integer | Offsetting advantage |
|---|---|---|
| Large OEM buyer power | Pricing pressure, forecast changes, and supplier diversification | Embedded programs, breadth, quality systems, and speed to market |
| Specialist suppliers | Deep expertise in a narrow process or component | Cross-selling and end-to-end integration across multiple processes |
| Insourcing and dual sourcing | Volume loss and lower utilization | OEM access to flexible capacity and specialized engineering without full internal investment |
| New technology | Existing products can become obsolete | RD&E, tuck-in acquisitions, and early participation in customer programs |
Who owns Integer stock, and how is governance changing?
Integer has one common share class and dispersed ownership rather than founder control. The 2026 proxy identifies BlackRock as the only holder above 5% known to the company, with 5,131,033 shares, or 15.06% of the class, based on its cited Schedule 13G. Directors and executive officers as a group held 377,261 shares, or 1.10%, as of March 30, 2026. CEO Payman Khales held 61,854 shares. This structure makes institutional voting and board credibility more important than insider voting control.
| Holder or group | Stake | Source period | Why it matters |
|---|---|---|---|
| BlackRock, Inc. | 5,131,033 shares; 15.06% | Proxy disclosure based on July 17, 2025 Schedule 13G | Large passive-manager influence in director elections and major transactions |
| Directors and executive officers | 377,261 shares; 1.10% | March 30, 2026 | Economic alignment exists, but insiders do not control outcomes |
| Board nominees | 10 of 11 independent | 2026 proxy | Oversight is formally independent, including audit and compensation committees |
| Shares outstanding | 34,070,093 | March 30, 2026 | Basis for ownership percentages and voting power |
Why are the activist agreement and strategic review important?
In March 2026, Integer entered a cooperation agreement with Irenic Capital and added directors with transaction, financial, and medtech experience. The official cooperation-agreement Form 8-K changed the governance context. In April, the board announced a review of a sale, merger, strategic combination, or continued standalone execution. The strategic review announcement does not guarantee a transaction, but it means valuation analysis must consider both operating performance and governance-driven optionality.
Leadership also changed recently. Khales became CEO in October 2025 after leading Cardio & Vascular and later serving as chief operating officer. The company said that business doubled sales during his seven-year leadership period, making execution in the largest product line a relevant credential. The official CEO transition release provides the succession context, while the 2026 proxy statement details ownership, incentives, and board independence.
Opportunities, risks, and the metrics that matter
Where could growth come from?
The strongest opportunity is deeper participation in structural heart, electrophysiology, neurovascular, cardiac rhythm management, and emerging neuromodulation programs. Coatings and micro-machining acquisitions can increase content per device and widen the number of problems Integer can solve for the same OEM. The company can also improve returns by filling capacity, standardizing operations through the Integer Production System, and shifting the mix away from Portable Medical. Management’s long-term goal of organic growth 200 basis points above its end markets is useful, but it remains an objective rather than a guaranteed outcome.
Which risks could change the story?
| Risk | Financial transmission | What to monitor |
|---|---|---|
| Customer concentration | Lower orders can reduce revenue and factory absorption quickly | Top-customer shares, forecast revisions, insourcing, and dual sourcing |
| New-product execution | Delayed ramps can create excess labor, inventory, and equipment costs | Cardio & Vascular organic growth and management commentary on the three headwinds |
| Quality and regulation | Remediation, recalls, validation delays, or lost customer trust | Regulatory disclosures, quality costs, and customer-transfer timing |
| Leverage and acquisition integration | Interest, amortization, and integration costs can dilute operating gains | Net leverage, cash conversion, goodwill, and synergy delivery |
| Strategic-review uncertainty | Advisory costs, distraction, or transaction risk | Board disclosures, formal offers, financing conditions, and standalone guidance |
What should researchers monitor next?
What is the key takeaway for valuation and research?
Integer is best understood as an engineered manufacturing platform embedded in regulated medical-device supply chains. Its value does not come from selling a branded therapy directly; it comes from being designed into customers’ products, operating validated processes, and supplying difficult components and assemblies at scale. The core strengths are Cardio & Vascular breadth, implantable-device expertise, quality systems, customer relationships, and a portfolio expanded through tuck-in acquisitions.
Which variables belong in a DCF?
A defensible DCF should focus on organic revenue growth by product line, gross-margin recovery as new programs ramp, operating expense discipline, normalized working capital, capital expenditure, acquisition-related amortization, cash taxes, and leverage. Terminal assumptions should reflect both the durability of regulated customer programs and the bargaining power of concentrated OEM buyers. Scenario analysis is especially important: one case can assume product-ramp recovery and better utilization, while another can assume prolonged customer headwinds, weaker margins, and slower deleveraging.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.